Publication:
Objective response rate is a surrogate marker for long-term overall survival in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors

Placeholder

Organizational Units

Program

KU Authors

Co-Authors

Arslan, Cagatay
Olmez, Omer Fatih
Erman, Mustafa
Urun, Yuksel
Erdem, Dilek
Kilickap, Saadettin

Advisor

Publication Date

Language

en

Journal Title

Journal ISSN

Volume Title

Abstract

Background: This study aimed to evaluate the utility of RECIST criteria-based objective response rate (ORR) as a potential surrogate endpoint for long-term overall survival (OS) in patients with metastatic urothelial carcinoma who were treated with immune checkpoint inhibitors (ICIs). Methods: The primary endpoint was overall ORR and OS, duration of treatment (DoR) with ICIs. ORR was analyzed using Fisher's exact test. Median follow-up and OS were estimated by using the Kaplan-Meier method. Results: The median follow-up was 58 (1.15-71) months. Progression developed in 94 (47%) patients during the first 3 months of ICIs therapy. The treatment response to ICIs included complete response (CR), partial response (PR) and stable disease in 10% (n = 20), 23% (n = 46), and 20% (n = 41) of patients, respectively. The responder and nonresponder groups differed in terms of certain baseline characteristics, such as Bellmunt risk factors, and neutrophil-to-lymphocyte ratio (NLR). The 5-year OS rates for patients with CR and PR were 73% and 23%, respectively. The median DoR for CR, PR, and SD were 51.8 months (44.5-59.1), 20.7 months (16.7-24.6), and 8.8 months (5.5-12.1), respectively. Overall, 16(80%) patients with CR and 14(30%) patients with PR had an ongoing response at the time of the analysis. In the univariate analysis, NLR > 3, liver metastases, ECOG PS >= 1, and hemoglobin levels < 10 mg/dl, as well as the PR and CR, were all significantly associated with OS. In multivariate analysis, presence of liver metastases (HR 2.3;95% CI, 1.3-4.2;P < .004) was found to be an independent determinant of short OS, while PR (HR 0.3;95% CI, 0.15-0.5;P < .001) and CR (HR 0.06;95% CI, 0.014-0.27;P < .001) were associated with improved OS. Conclusions: In conclusion, this 5-year analysis of real-world data in the setting of metastatic urothelial cancer indicated a significant correlation between ORR, especially CR, and OS in patients who received ICIs. Therefore, identifying a potential surrogate marker for survival in patients treated with ICIs would represent an important advance in the early identification of patients' response or resistance to ICIs.

Description

Source:

Clinical Genitourinary Cancer

Publisher:

CIG MEDIA GROUP, LP

Keywords:

Subject

Oncology, Urology and nephrology

Citation

Endorsement

Review

Supplemented By

Referenced By

Copy Rights Note

0

Views

0

Downloads

View PlumX Details